Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial

Aim We conducted a multicentre, randomized phase 3 trial in China to evaluate the efficacy and safety of cofrogliptin (HSK7653), a novel long‐acting dipeptidyl peptidase‐4 inhibitor, in patients with drug‐naïve type 2 diabetes (T2D). Materials and Methods Patients with inadequately controlled T2D we...

Full description

Saved in:

Bibliographic Details
Published in:	Diabetes, obesity & metabolism obesity & metabolism, 2025-01, Vol.27 (1), p.280-290
Main Authors:	Gao, Leili, Bian, Fang, Pan, Tianrong, Jiang, Hongwei, Feng, Bo, Jiang, Chengxia, Sun, Jia, Xiao, Jianzhong, Yan, Pangke, Ji, Linong
Format:	Article
Language:	English
Subjects:	Adult Aged Blood Glucose - drug effects China Clinical trials cofrogliptin Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl-Peptidase IV Inhibitors - administration & dosage Dipeptidyl-Peptidase IV Inhibitors - adverse effects Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Double-Blind Method Drug Administration Schedule East Asian People Female glycated haemoglobin Glycated Hemoglobin - analysis Glycated Hemoglobin - drug effects Hemoglobin Humans Hyperlipidemia Hyperuricemia Hypoglycemia - chemically induced Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use long‐acting DPP4‐inhibitor Male Middle Aged Original Placebos randomized controlled trial Respiration Respiratory tract infection Treatment Outcome type 2 diabetes Urinary tract
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!